Sarissa Capital Management LP holds a concentrated book of 9 stocks worth $157.6M as of Q1 2026 (disclosed May 15, 2026, a ~45-day 13F lag). This quarter they trimmed Innoviva Inc. Their largest long position is Innoviva Inc at 31% of the equity book.
Top-heavy: concentrated book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
100% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Other tracked managers holding the same core names as Sarissa Capital Management LP
| Manager / fund | Shared names | Their $ in those |
|---|---|---|
| BlackRock, Inc. | 9 / 9 | $10.8B |
| STATE STREET CORP | 9 / 9 | $4.8B |
| JPMORGAN CHASE & CO | 9 / 9 | $4.1B |
| GEODE CAPITAL MANAGEMENT, LLC | 9 / 9 | $2.6B |
| MORGAN STANLEY | 9 / 9 | $1.5B |
| GOLDMAN SACHS GROUP INC | 9 / 9 | $1.3B |
| UBS Group AG | 9 / 9 | $629.8M |
| BNP PARIBAS FINANCIAL MARKETS | 9 / 9 | $472.4M |
Ranked by the share of each fund's own book sitting in the names it shares with Sarissa Capital Management LP: only funds sharing at least a tenth of the book qualify. Index giants, bank custody books and market makers are excluded. They hold everything, so their overlap says nothing.
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Innoviva Inc COM | $49.7M | 2.13M | 31.5% | ▼−24% Reduced · −685K sh | |
| 2 | Ironwood Pharmaceuticals Inc COM CL A | $32.3M | 9.19M | 20.5% | ▼−42% Reduced · −6.7M sh | |
| 3 | Amarin Corp PLC SPONSORED ADR | $24.2M | 1.67M | 15.4% | —Held | |
| 4 | Neurocrine Biosciences Inc COM | $15.4M | 116.5K | 9.7% | ▼−62% Reduced · −187K sh | |
| 5 | Cytokinetics Inc COM NEW | $15.1M | 228.6K | 9.6% | ▼−42% Reduced · −168K sh | |
| 6 | Lantheus Hldgs Inc COM | $12.7M | 166.9K | 8.0% | ▼−8.0% Reduced · −15K sh | |
| 7 | Biohaven Ltd COM | $4.8M | 563.2K | 3.0% | ▲+9.7% Added · +50K sh | |
| 8 | Regeneron Pharmaceuticals COM | $3.2M | 4.2K | 2.1% | —Held | |
| 9 | Vor Biopharma Inc COM NEW | $453K | 25.4K | 0.3% | —Held |
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/1577524/holdings"
Use Arkolith to show Sarissa Capital Management LP's latest holdings, largest changes, and filing provenance.
As-of date vs the date the SEC received each filing
Holdings from SEC EDGAR 13F-HR filings, updated quarterly, filed up to 45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. Price-derived performance is withheld until the price-source policy and freshness gate are green.